Zentalis (ZNTL) Locks In Its Cancer Drug Dose; Jefferies Raises the Target [Yahoo! Finance]
Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026
Zentalis Pharmaceuticals (ZNTL) had its price target raised by Guggenheim from $6.00 to $10.00. They now have a "buy" rating on the stock.
Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer
Zentalis Pharmaceuticals (ZNTL) had its "sell (d-)" rating reaffirmed by
Weiss Ratings.